JonesTrading analyst Prakhar Agrawal maintained a buy rating on Arena Pharmaceuticals on Monday, setting a price target of $ 92, or about 53.13% above the current share price of $ 60.08.
Agrawal expects Arena Pharmaceuticals to post earnings per share (EPS) of – $ 2.40 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of stocks in Arena Pharma (NASDAQ :), with an average price target of $ 94.86.
Analysts’ price targets range from a high of $ 120 to a low of $ 76.
In its latest earnings report, released on 6/30/2021, the company reported quarterly revenue of $ 0 and net income of – $ 144.35 million. The company’s market capitalization is $ 3.67 billion.
According to TipRanks.com, JonesTrading analyst Prakhar Agrawal is currently rated with 3 stars on a 0 to 5 star rating scale, with an average return of 5.8% and a success rate of 40.48%.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel drugs targeting G protein coupled receptors. It provides drugs for the treatment of cardiovascular, central nervous system, inflammatory diseases and metabolic. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, California.
Fusion media or anyone involved with Fusion Media will accept no responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.